GlassScriptPhysician profile
Sarina Ahuja
NPI 1821275827
$495.26
in general payments reported to CMS, 2019-2025
10 companies · $50.06 in 2025
The $50.06 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.90 · 2021: $17.82 · 2022: $59.32 · 2023: $23.90 · 2024: $325 · 2025: $50.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369 · Education: $29.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.43 |
| Education | $29.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.00 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $109.26 | 2024 | Terlivaz |
| Akebia Therapeutics INC | $73.49 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.87 | 2022-2024 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $30.93 | 2024 | |
| Travere Therapeutics, INC. | $29.79 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $23.47 | 2025 | Velphoro |
| Vifor Pharma, INC. | $22.88 | 2025 | Veltassa |
| Novo Nordisk INC | $17.74 | 2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $14.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarina Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.